See All Slides - tctmd.com

Slides

Presentation TCT 2012

When Should MVD be Managed Medically?

Presenter: William Boden

October 23, 2012

Presentation TCT 2012

TCT-38. Two-year Clinical Data of Cohort 1 and Multi-modality Imaging Results Up to 1-year Follow-up of the BIOSOLVE-I Study with the Paclitaxel-eluting Bioabsorbable...

Presenter: Michael Haude

October 23, 2012

Presentation TCT 2012

Essentials of Carotid Artery Diseases: Guidelines, Assessment, and Outcomes

Presenter: Jose Wiley

October 23, 2012

Presentation TCT 2012

Surgical Perspectives of the MitraClip and Its Role in the Treatment of Severe Degenerative and Functional MR

Presenter: Hendrik Treede

October 23, 2012

Presentation TCT 2012

Pathogenesis of Vulnerable Plaque 2012: What's New?

Presenter: Renu Virmani

October 23, 2012

Presentation TCT 2012

Practice Trends in the United States: Nonadherence to the Mitral Valve Guidelines

Presenter: James Gammie

October 23, 2012

Presentation TCT 2012

Debate II. Is Straight-Line Flow to the Foot Sufficient (And Is the Angiosome Concept Nonsense)? Con!

Presenter: Andrej Schmidt

October 23, 2012

Presentation TCT 2012

Is Ischemia a Marker of Plaque Vulnerability and Future Thrombosis?

Presenter: Bernard De Bruyne

October 23, 2012

Presentation TCT 2012

Case 1: During a TAVR

Presenter: Susheel Kodali

October 23, 2012

Presentation TCT 2012

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Presenter: Joseph Jakubowski

October 23, 2012

Advertisement

Slides

When Should MVD be Managed Medically?

TCT-38. Two-year Clinical Data of Cohort 1 and Multi-modality Imaging Results Up to 1-year Follow-up of the BIOSOLVE-I Study with the Paclitaxel-eluting Bioabsorbable...

Essentials of Carotid Artery Diseases: Guidelines, Assessment, and Outcomes

Surgical Perspectives of the MitraClip and Its Role in the Treatment of Severe Degenerative and Functional MR

Pathogenesis of Vulnerable Plaque 2012: What's New?

Practice Trends in the United States: Nonadherence to the Mitral Valve Guidelines

Debate II. Is Straight-Line Flow to the Foot Sufficient (And Is the Angiosome Concept Nonsense)? Con!

Is Ischemia a Marker of Plaque Vulnerability and Future Thrombosis?

Case 1: During a TAVR

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content